These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31752716)

  • 1. Intra-abdominal infections: the role of different classifications on the selection of the best antibiotic treatment.
    Silva-Nunes J; Cardoso T
    BMC Infect Dis; 2019 Nov; 19(1):980. PubMed ID: 31752716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
    Prabhu V; Foo J; Ahir H; Sarpong E; Merchant S
    J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic Resistance in Community-Acquired Intra-Abdominal Infections: Diabetes Mellitus as a Risk Factor.
    Núñez SA; Lacal V; Núñez J; Serruto G; Zárate MS; Verón MT
    Surg Infect (Larchmt); 2020 Feb; 21(1):62-68. PubMed ID: 31441705
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis.
    Grau S; Lozano V; Valladares A; Cavanillas R; Xie Y; Nocea G
    Appl Health Econ Health Policy; 2015 Aug; 13(4):369-79. PubMed ID: 25761545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
    Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
    Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology and Risk Factors for Isolation of Multi-Drug-Resistant Organisms in Patients with Complicated Intra-Abdominal Infections.
    Labricciosa FM; Sartelli M; Abbo LM; Barbadoro P; Ansaloni L; Coccolini F; Catena F
    Surg Infect (Larchmt); 2018 Apr; 19(3):264-272. PubMed ID: 29298133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does Isolation of Enterococcus Affect Outcomes in Intra-Abdominal Infections?
    Sanders JM; Tessier JM; Sawyer R; Dellinger EP; Miller PR; Namias N; West MA; Cook CH; O'Neill PJ; Napolitano L; Rattan R; Cuschieri J; Claridge JA; Guidry CA; Askari R; Banton K; Rotstein O; Moore BJ; Duane TM
    Surg Infect (Larchmt); 2017; 18(8):879-885. PubMed ID: 28994635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial Susceptibilities of Aerobic and Facultative Gram-Negative Bacilli from Intra-abdominal Infections in Patients from Seven Regions in China in 2012 and 2013.
    Zhang H; Yang Q; Liao K; Ni Y; Yu Y; Hu B; Sun Z; Huang W; Wang Y; Wu A; Feng X; Luo Y; Hu Z; Chu Y; Chen S; Cao B; Su J; Gui B; Duan Q; Zhang S; Shao H; Kong H; Badal RE; Xu Y
    Antimicrob Agents Chemother; 2016 Jan; 60(1):245-51. PubMed ID: 26482308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
    Popejoy MW; Long J; Huntington JA
    BMC Infect Dis; 2017 May; 17(1):316. PubMed ID: 28464828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of moxifloxacin for the treatment of community-acquired [corrected] complicated intra-abdominal infections in Taiwan.
    Lau YJ; Chen YH; Huang CT; Lee WS; Liu CY; Liu JW; Liu HD; Lee YJ; Chen CW; Ko WC; Hsueh PR
    J Microbiol Immunol Infect; 2012 Feb; 45(1):1-6. PubMed ID: 22244019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.
    Maseda E; Aguilar L; Gimenez MJ; Gilsanz F
    Expert Rev Anti Infect Ther; 2014 Nov; 12(11):1311-24. PubMed ID: 25139127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options.
    Golan Y
    BMC Infect Dis; 2015 Aug; 15():313. PubMed ID: 26243291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Safety of Tigecycline Compared with Other Broad-Spectrum Antimicrobials in Abdominal Solid Organ Transplant Recipients with Polymicrobial Intraabdominal Infections.
    Liebenstein T; Schulz LT; Viesselmann C; Bingen E; Musuuza J; Safdar N; Rose WE
    Pharmacotherapy; 2017 Feb; 37(2):151-158. PubMed ID: 27983753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of tazobactam/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections.
    Mikamo H; Monden K; Miyasaka Y; Horiuchi T; Fujimoto G; Fukuhara T; Yoshinari T; Rhee EG; Shizuya T
    J Infect Chemother; 2019 Feb; 25(2):111-116. PubMed ID: 30528561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiological study of community- and hospital-acquired intraabdominal infections.
    Zhang S; Huang W
    Chin J Traumatol; 2015; 18(2):84-9. PubMed ID: 26511299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra-Abdominal Infections: Prevalence and Risk Factors of ESBLs Infections.
    Boontham P; Soontomrak R
    J Med Assoc Thai; 2015 Nov; 98(11):1097-103. PubMed ID: 26817180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Nasal Methicillin-Resistant Staphylococcus aureus Screening Be Used to Avoid Empiric Vancomycin Use in Intra-Abdominal Infection?
    Hennessy SA; Shah PM; Guidry CA; Davies SW; Hranjec T; Sawyer RG
    Surg Infect (Larchmt); 2015 Aug; 16(4):396-400. PubMed ID: 26069990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology and susceptibility of pathogens from SMART 2011-12 Turkey: evaluation of hospital-acquired versus community-acquired urinary tract infections and ICU- versus non-ICU-associated intra-abdominal infections.
    Koksal I; Yilmaz G; Unal S; Zarakolu P; Korten V; Mulazimoglu L; Tabak F; Mete B; Oguz VA; Gulay Z; Alp E; Badal R; Lob S
    J Antimicrob Chemother; 2017 May; 72(5):1364-1372. PubMed ID: 28122913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoroquinolone-based versus β-lactam-based regimens for complicated intra-abdominal infections: a meta-analysis of randomised controlled trials.
    Mavros MN; Theochari NA; Kyriakidou M; Economopoulos KP; Sava JA; Falagas ME
    Int J Antimicrob Agents; 2019 Jun; 53(6):746-754. PubMed ID: 30639629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibilities of specific syndromes created with organ-specific weighted incidence antibiograms (OSWIA) in patients with intra-abdominal infections.
    Liu L; Ni Y
    BMC Infect Dis; 2018 Nov; 18(1):584. PubMed ID: 30453893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.